Cerebral ischemia–reperfusion injury occurs when blood supply to the brain is temporarily interrupted and then restored, paradoxically leading to further neuronal damage. One of the pathological mechanisms responsible for such injury is programmed cell death. RIPK1, a serine/threonine kinase, has emerged as a master regulator orchestrating necroptosis and apoptosis during I/R events. Necroptosis is a form of regulated necrosis characterized by cellular swelling and membrane rupture, while apoptosis is a form of programmed cell death involving cellular shrinkage and DNA fragmentation. Both pathways contribute significantly to ischemic brain injury.

Despite the pivotal role of RIPK1 in mediating cell death, the precise regulatory checkpoints governing its activation in the context of cerebral I/R injury have remained unknown until now. The investigative team, led by scientists including Tengfei Liu, Gan Huang, and colleagues, explored the role of PRMT1, a protein that methylates arginine residues on target proteins, thereby modulating their function. Their findings reveal that PRMT1 expression is markedly downregulated following cerebral I/R injury, setting off a cascade that culminates in the activation of RIPK1.

Mechanistically, the study demonstrates that PRMT1 physically interacts with RIPK1 and catalyzes asymmetric dimethylation of its arginine residues. This post-translational modification effectively inhibits RIPK1 homodimerization—a prerequisite for its kinase activation. Inhibition of homodimerization leads to the suppression of RIPK1’s kinase activity, which in turn prevents the initiation of downstream cell death pathways such as necroptosis and apoptosis. This regulatory axis provides a novel molecular safeguard against excessive neuronal death.

To validate the functional significance of this interaction, the researchers employed pharmacological inhibitors and genetic ablation techniques to reduce PRMT1 activity in experimental models of cerebral I/R injury. Under these conditions, they observed exacerbated brain damage characterized by increased RIPK1 activation and enhanced necroptotic and apoptotic cell death. Conversely, overexpression of PRMT1 conferred neuroprotection by attenuating RIPK1 activity and reducing neuronal loss.

This dual approach highlights the potential of PRMT1 modulation as a therapeutic strategy. The attenuation of RIPK1-mediated necroptosis and apoptosis through restoring or augmenting PRMT1 activity could serve as a novel intervention point to mitigate ischemic stroke outcomes. The study further reinforces the complexity of post-translational modifications in fine-tuning kinase signaling and cell fate decisions under pathological conditions.

The study also advances our understanding of the crosstalk between methylation and phosphorylation events in regulating intracellular signaling during brain injury. Arginine methylation carried out by enzymes such as PRMT1 represents a reversible and dynamic modification that can modulate protein-protein interactions and enzymatic activities. In the context of cerebral I/R injury, PRMT1-dependent methylation of RIPK1 acts as an inhibitory checkpoint that restrains kinase-driven cell death.

Necroptosis, driven by RIPK1 kinase activity, involves the recruitment and phosphorylation of mixed lineage kinase domain-like pseudokinase (MLKL), leading to plasma membrane permeabilization and necrotic cell death. Apoptosis, on the other hand, is characterized by caspase activation and cellular dismantling. RIPK1 is uniquely positioned as a signaling hub that determines cell fate by balancing these pathways. The identification of PRMT1 as a negative regulator of RIPK1 highlights a sophisticated molecular switch controlling neuronal survival.

Given the high global burden of ischemic stroke and the limited therapeutic options currently available, the discovery of PRMT1’s protective role against cerebral I/R injury carries significant clinical implications. Strategies aimed at enhancing PRMT1 activity or mimicking its methylation effect on RIPK1 may limit the extent of neuronal damage and improve neurological recovery in stroke patients.

Moreover, the study underscores the value of targeting post-translational modifications as a pharmacological approach. Unlike irreversible genetic alterations, modulating enzyme activities such as PRMT1 offers potential reversibility and temporal control, making it an attractive route for drug development. Future research will be required to identify selective activators or stabilizers of PRMT1 that can be translated into clinical applications.

The authors also call attention to the necessity for deeper mechanistic studies to delineate whether PRMT1 exerts additional neuroprotective effects beyond RIPK1 methylation. It is plausible that PRMT1 may regulate other signaling targets or pathways involved in inflammation, oxidative stress, or cellular metabolism during cerebral ischemia–reperfusion injury. Comprehensive proteomic and interactome analyses may uncover such layers of regulation.

In conclusion, the elucidation of PRMT1 as a key modulator that suppresses RIPK1-mediated necroptosis and apoptosis represents a landmark advancement in stroke biology. This work not only enriches our molecular understanding of neuronal cell death regulation but also establishes PRMT1 as a promising target for the development of therapies aimed at protecting the brain from ischemic injury. As research progresses, it will be critical to translate these insights into pharmacological strategies that can effectively reduce morbidity and mortality associated with ischemic stroke worldwide.

Subject of Research: Regulation of RIPK1 kinase activity and neuronal cell death mechanisms in cerebral ischemia–reperfusion injury

Article Title: The protein arginine methyltransferase PRMT1 ameliorates cerebral ischemia–reperfusion injury by suppressing RIPK1-mediated necroptosis and apoptosis

News Publication Date: 2025

Web References:

• Acta Pharmaceutica Sinica B: https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b
• DOI: http://dx.doi.org/10.1016/j.apsb.2025.06.005

References:
Liu, T., Huang, G., Guo, X., Ji, Q., Yu, L., Zong, R., Li, Y., Song, X., Fu, Q., Xue, Q., Zheng, Y., Zeng, F., Sun, R., Chen, L., Gao, C., Liu, H. (2025). The protein arginine methyltransferase PRMT1 ameliorates cerebral ischemia–reperfusion injury by suppressing RIPK1-mediated necroptosis and apoptosis. Acta Pharmaceutica Sinica B, 15(8), 4014-4029.

Keywords: PRMT1, Cerebral ischemia–reperfusion injury, RIPK1, Arginine methylation, Necroptosis, Apoptosis, Phosphorylation, MLKL

At the core of this study lies the concept of HRV, a complex physiological phenomenon representing the fluctuations in intervals between heartbeats, known as RR intervals. HRV serves as a crucial marker of autonomic nervous system function and cardiovascular health. Variations in HRV are indicative of the intricate balance between the sympathetic and parasympathetic branches that regulate cardiac function. Stroke survivors often experience autonomic dysregulation, making HRV a compelling target for clinical investigation.

The researchers recruited twelve post-stroke patients, averaging 55.3 years of age, with a predominance of female participants, to engage in a two-session experimental protocol. The first session focused on familiarizing patients with the RATT system and calibrating the biofeedback mechanisms responsible for maintaining a predefined HR setpoint during exercise. This calibration was essential for establishing an automatic feedback control loop, ensuring precise HR modulation during subsequent physical activity.

In the second session, participants underwent a structured sequence comprising fourteen minutes of rest, followed by twenty-one minutes of active exercise on the tilt table. The exercise phase was uniquely controlled—heart rate was kept constant through real-time biofeedback from a chest-belt sensor measuring HR, with the system adjusting physical parameters to counteract cardiovascular drift. This approach minimized confounding factors such as fatigue or stress-induced HR elevations, allowing for a clearer analysis of time- and intensity-dependent HRV changes.

Data acquisition utilized raw RR intervals, capturing the minute-to-minute heartbeat spacing essential for HRV computation. The team segmented the rest period into two equal intervals (0–7 minutes and 7–14 minutes) and similarly divided exercise intervals (5–13 minutes and 13–21 minutes) to assess temporal changes. This segmentation underscored the dynamic nature of HRV, revealing nuanced physiological responses during rest and controlled exertion in the post-stroke cohort.

Findings demonstrated unequivocal reductions in HRV during exercise compared to rest, reflecting typical autonomic shifts favoring sympathetic dominance under physical stress. Interestingly, HRV values during the initial rest period (0–7 minutes) were lower than those observed in the latter half (7–14 minutes), correlating with a subtle reduction in resting HR over time. This pattern suggests an adaptive autonomic recalibration as the body stabilizes after positioning on the tilt table.

During exercise, a distinct time-dependent decline in HRV was documented. Early-phase exercise (5–13 minutes) exhibited higher HRV than the later phase (13–21 minutes), indicating progressive autonomic modulation with ongoing activity, even under constant HR conditions. This phenomenon highlights the sensitivity of HRV as a marker for physiological strain and cardiac adaptability during stroke rehabilitation.

The study’s application of a biofeedback-enhanced RATT introduces a groundbreaking methodology for heart rate-controlled exercise in neurologically impaired populations. By combining robotics and real-time cardiovascular monitoring, this platform surpasses traditional rehabilitation devices, offering precise control over exercise intensity and physiological load. Such precision is vital for tailoring rehab interventions to optimize cardiovascular conditioning without overburdening compromised autonomic systems.

Beyond clinical applications, the implications of this research extend into the realm of personalized medicine. Understanding the temporal and intensity-dependent profiles of HRV post-stroke enables clinicians to prescribe exercise regimens attuned to individual autonomic responsiveness. This approach promises to enhance safety, efficacy, and patient adherence, potentially accelerating functional recovery and reducing secondary cardiovascular risks.

Furthermore, the study’s methodology paves the way for integrating advanced feedback control systems in other cardiovascular and neurological rehabilitation contexts. The seamless blend of technology and physiology showcased here exemplifies the future direction of bioengineering—where real-time data inform adaptive therapeutic interventions, minimizing human error and maximizing patient-specific outcomes.

Importantly, the investigation also provides foundational data supporting the design of larger-scale clinical trials. The feasibility demonstrated herein confirms that stroke patients can tolerate and benefit from controlled exercise protocols governed by robotic assistance and biofeedback, setting the stage for comprehensive studies evaluating long-term impacts on autonomic function and overall rehabilitation progress.

In summary, this pioneering work illuminates the nuanced interplay between heart rate variability and controlled exercise in stroke survivors, facilitated by an ingenious biofeedback robotics-assisted system. By elucidating the temporal dynamics of HRV at rest and during exertion, the study offers critical insights that could revolutionize cardiovascular rehabilitation. The potential to harness such technology in clinical practice heralds a new era of precision medicine for stroke recovery, underscoring the vital role of biomedical engineering in transforming medical care.

As biomedical research continues to converge with innovative engineering, studies like this highlight the transformative power of interdisciplinary collaboration. The ability to quantifiably monitor and modulate cardiac function in vulnerable populations is not only a testament to technological progress but also a beacon of hope for improved quality of life and functional independence among stroke survivors worldwide.

Subject of Research: Changes in heart rate variability at rest and during exercise in patients after a stroke using biofeedback-enhanced robotics-assisted tilt table technology.

Article Title: Changes in heart rate variability at rest and during exercise in patients after a stroke: a feasibility study

Article References:
Saengsuwan, J., Brockmann, L., Schuster-Amft, C. et al. Changes in heart rate variability at rest and during exercise in patients after a stroke: a feasibility study. BioMed Eng OnLine 23, 132 (2024). https://doi.org/10.1186/s12938-024-01328-7

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12938-024-01328-7